tak 779 has been researched along with flupenthixol in 1 studies
Studies (tak 779) | Trials (tak 779) | Recent Studies (post-2010) (tak 779) | Studies (flupenthixol) | Trials (flupenthixol) | Recent Studies (post-2010) (flupenthixol) |
---|---|---|---|---|---|
118 | 1 | 35 | 929 | 128 | 138 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berman, JW; Gaskill, PJ; Javitch, JA; Kalpana, GV; Yano, HH | 1 |
1 other study(ies) available for tak 779 and flupenthixol
Article | Year |
---|---|
Dopamine receptor activation increases HIV entry into primary human macrophages.
Topics: Amides; CCR5 Receptor Antagonists; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Flupenthixol; Gene Expression; HIV Fusion Inhibitors; HIV-1; Humans; Macrophages; Primary Cell Culture; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, Dopamine D1; Receptors, Dopamine D2; Virus Internalization | 2014 |